ReviewCurrent opinion in immunology2021
Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections.
Review in Current opinion in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 82 citations in OpenAlex.
- CHAPLE-Like Enteropathy and Renal Microangiopathy in an Adult Patient With CD46 Deficiency.Journal of clinical laboratory analysis · 2026Article
- Advances in Complement Research: from Pathophysiology to Precision Medicine.Physiology (Bethesda, Md.) · 2026Review
- A three-gene radioresistance signature predicts tumor progression in cervical cancer.Translational cancer research · 2026Article
- Association of Complement Genetics with Outcomes in IgA Nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Comprehensive Prediction Analysis of Novel Noncoding Regulatory Variants Identified in the MicroRNA Binding Regions in Complement System Genes.International journal of molecular sciences · 2026Article
- Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies.International journal of molecular sciences · 2026Review
- The Complement System in the Setting of Critical Illness-A Narrative Review.Biomolecules · 2026Review
- Comprehensive cancer analysis reveals CFH as an immune-related and prognostic marker.BMC cancer · 2025Article
- Identification of a new CD46 gene mutation site in a family with atypical hemolytic uremic syndrome.BMC nephrology · 2025Article
- Inside job: Roles of intracellular C3.The Journal of allergy and clinical immunology · 2025Review
- Integrating single-cell and bulk RNA sequencing data to construct a pyroptosis-related prognostic signature and analyze the tumor microenvironment in gastric cancer.Translational cancer research · 2025Article
- The multiverse of CD46 and oncologic interactions.The Journal of clinical investigation · 2025Review
- The complement system in human pregnancy and preeclampsia.Frontiers in immunology · 2025Review
- Exploring the interaction mechanisms of CD46/TREM1 and LC3B/ATG5 in the inflammation-cancer transformation of oral squamous cell carcinoma based on bioinformatics.Frontiers in molecular biosciences · 2025Article
- CD46 TREM1 regulates the autophagy marker LC3B ATG5 in oral squamous cell carcinoma.Frontiers in oncology · 2025Article
- Exploring the exoproteome of the parasitic nematodeFrontiers in immunology · 2025Article
- Protein-losing enteropathy as a new phenotype in atypical hemolytic uremic syndrome caused by CD46 gene mutation.Pediatric nephrology (Berlin, Germany) · 2024Review
- CD46 Is a Protein Receptor for Human Adenovirus Type 64.Viruses · 2024Article
- Shedding of membrane complement inhibitors CD59 and CD46 into the circulation is associated with poor prognosis in acute coronary syndrome patients: a cohort study.Journal of translational medicine · 2024Article
- Systematic Review of Individual Patient Data COVID-19 Infection and Vaccination-Associated Thrombotic Microangiopathy.Kidney international reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Membrane cofactor protein (MCP; CD46), a ubiquitously expressed complement regulatory protein, serves as a cofactor for serine protease factor I to cleave and inactivate C3b and C4b deposited on host cells. However, CD46 also plays roles in human reproduction, autophagy, modulating T cell activation and effector functions and is a member of the newly identified intracellular complement system (complosome). CD46 also is a receptor for 11 pathogens ('pathogen magnet'). While CD46 deficiencies contribute to inflammatory disorders, its overexpression in cancers and role as a receptor for some adenoviruses has led to its targeting by oncolytic agents and adenoviral-based therapeutic vectors, including coronavirus disease of 2019 (COVID-19) vaccines. This review focuses on recent advances in identifying disease-causing CD46 variants and its pathogen connections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.